Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Despite significant advances in the diagnostic services and patient care, several gaps remain to be addressed, from early detection, to identifying prognostic variables, effective treatment for the metastatic disease, and the implementation of tailored treatment strategies. MicroRNAs, the short non-coding RNA species, are deregulated in CRC and play a significant role in the occurrence and progression. Nevertheless, microRNA research has historically been based on expression levels to determine its biological significance. The exact mechanism underpinning microRNA deregulation in cancer has yet to be elucidated, but several studies have demonstrated that epigenetic mechanisms play important roles in the regulation of microRNA expression, particularly DNA methylation. However, the methylation profiles of microRNAs remain unknown in CRC patients. Methylation is the next major paradigm shift in cancer detection since large-scale epigenetic alterations are potentially better in identifying and classifying cancers at an earlier stage than somatic mutations. This review aims to provide insight into the current state of understanding of microRNA methylation in CRC. The new knowledge from this study can be utilized for personalized health diagnostics, disease prediction, and monitoring of treatment.

Keywords: microRNA; colorectal cancer; epigenetics; methylation; biomarker

1. Introduction

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. The economic burden of CRC management of new cases in Malaysia is estimated at MYR 62 million per year [1]. While there have been significant advancements in diagnostic services and patient care, several gaps remain, from early detection to the identification of prognostic variables, the effective treatment of metastatic disease, and the implementation of customized treatment strategies. A quite recent study concludes that CRC is an expensive disease, with provider costs ranging from MYR 13,672 for stage I to MYR 27,972 for stage IV [2].

Cancer is a global burden with over 14.1 million new incidences in 2012 and is projected to increase in the next decade. In Malaysia, CRC is the most common cancer, with an overall incidence rate of 21.3 cases per 100,000 population [3]. Many CRC studies have
revealed molecular alterations involved in its pathogenesis [4–6], yet the prognosis of advanced CRC is still dismal and the search continues for biomarkers which could accurately guide the medical practitioners in the management and treatment of CRC. Therefore, robust prognostic and predictive biomarkers are undoubtedly an important goal. One of the candidates for the biomarkers could be discovered by analyzing the epigenome of the tumors.

MicroRNAs are small (~22 nucleotides), non-coding RNAs that modulate gene expression in various eukaryotes [7]. These single-stranded RNAs exert their roles by interacting with specific target mRNAs through partial complementarity with sequences located mainly in the 3′ UTR, subsequently causing mRNA degradation or translational inhibition [7]. MicroRNAs perform critical roles in a variety of cellular processes, including apoptosis, cell cycle, proliferation, differentiation, and angiogenesis, by simultaneously regulating the expression levels of several genes. MicroRNAs are found in all tissues and play a function in every cell type [7]. A large number of studies in CRC have also revealed that microRNA expression profiles change remarkably between normal tissues and tumors, associated with drug resistance, as well as possess diagnostic, prognostic, and theranostic values [8–11]. Moreover, microRNAs play dual roles as oncogenes and tumor suppressors, which is the key function in tumorigenesis [12].

Although the specific mechanism underlying microRNA deregulation in cancer has yet to be determined, multiple studies have demonstrated that epigenetic mechanisms play a significant role in the regulation of microRNA expression in cancer cells [13–15], particularly DNA methylation, which is a biological process that adds methyl groups (CH$_3$) to the cytosine ring, producing 5-methylcytosine (5mC) (Figure 1a). Expression of microRNAs might be epigenetically regulated via DNA methylation of CpG islands located at promoter regions [13] (Figure 1b,c). Alterations in those mechanisms might perturb microRNAs expression, subsequently altering gene and protein expression, leading to cancer progression. The study of DNA methylation in microRNA genes is not entirely new. Publications on this topic began to emerge around a decade ago, yet the gap in knowledge remains, particularly in CRC. Most of the published data have been derived from CRC cell lines and not from clinical specimens [16,17]. In addition, to the best of our knowledge, there has been a limited number of publications on genome-wide microRNA methylome profiling in this cancer [18]. Most of the studies were focused on the selected microRNAs known to be hypermethylated in CRC, such as miR-34b/c, miR-124, miR-133b, and miR-324, etc. [19–21]. While reports on epigenome-wide microRNA methylation profiles have already been published in other cancers, such as pancreatic, breast, and oral cancers [22–24], studies on CRC are severely lacking.
Figure 1. Overview of the methylation process. (a) Methylation is defined as an addition of a methyl group to the cytosine ring. (b) When the microRNA gene is methylated, it will be switched off and the transcription process will stop. No mature microRNA will be expressed. (c) When there is absence of methylation, the microRNA gene will be switched on, therefore transcription will occur and mature microRNA will be expressed.

2. MicroRNA Methylation with Diagnostic and Prognostic Markers

MicroRNAs may function as tumor suppressor genes, and their downregulation is commonly detected in CRCs. Epigenetic regulation, including DNA methylation, is one of the mechanisms associated with microRNA silencing. Since epigenetic silencing is a reversible process, aberrant methylation of microRNA emerges as a novel class of biomarkers, with strong potential as diagnostic and prognostic markers in CRCs.

2.1. MiRNA-124a

MiR-124a is among the first microRNAs in CRC that have been shown to be silenced via an epigenetic mechanism [17,25]. It was discovered through a genetic unmasking experiment from a cell line model with disrupted DNA methyltransferases [17]. DNA
methylation of miR-124a may serve as an epigenetic biomarker for CRC, since this gene is more frequently methylated in CRCs than in other cancers [26]. Lujambio et al. have demonstrated that the epigenetic silencing of miR-124a via CpG island hypermethylation leads to the activation of cyclin D kinase 6 (CDK6), an oncogene, and the phosphorylation of the retinoblastoma (Rb) tumor suppressor gene [17]. The authors proved that miR-124a was specifically methylated in cancer cells, suggesting a tumor suppressive role [17]. Encoded by three independent loci (miR-124a-1, -2, and -3), miR-124a is associated with various CpG islands [13]. Aberrant DNA methylation of miR-124a-1, -2, and -3 was detected in bowel lavage fluid (BLF) specimen in CRC patients. Among these three genes, methylated miR-124a-3 showed the greatest sensitivity for CRC detection, highlighting the potential of this microRNA as a non-invasive diagnostic marker for CRC screening [27].

Ueda et al. [28] also reported that three miR-124a genes were methylated during carcinogenesis in patients with ulcerative colitis (UC). Nonetheless, methylation of miR-124a-3 was frequently detected in the early stage of colitis-associated cancer (CAC), indicating the importance of this microRNA in estimating the individual risk of developing CAC. Moreover, another related study found that miR-124a was methylated in UC patients with CRC. The authors identified higher methylation level in rectal tissues in an age-dependent manner [29]. Considered together, these two studies suggest that methylation of miR-124a is a potential marker for identifying UC patients with high risk of developing CRC.

Numerous studies have demonstrated the role of miR-124a as a prognostic biomarker in CRC patients. The miR-124a expression level varied depending on the tumor differentiation grades, while the low miR-124a was measured in tissues with moderate to poor differentiation. In addition, survival analysis of 96 CRC patients showed that the group with downregulated miR-124a exhibited worse prognosis in overall survival (OS) and disease-free survival (DFS) [30]. Similarly, Jinushi et al. [31] discovered the low expression of miR-124a in plasma samples of CRC patients with poor OS. Moreover, another study found that downregulation of miR-124a could induce cell proliferation, migration, invasion, and metastasis in CRC by negatively regulated ROCK1 expression [32]. In the future, miR-124a may constitute an effective new prognostic biomarker for CRC patients with advanced disease or metastasis.

2.2. MiRNA-137

MiR-137 is located on the chromosome 1p22 within the gene sequence of MIR137HG [33]. This microRNA is embedded in a CpG island and is often downregulated in several tumors, including CRC, due to the promoter hypermethylation [34–36]. Several studies have reported the potential use of miR-137 methylation as a diagnostic biomarker. In a study by Balaguer et al., miR-137 was epigenetically silenced in CRC cell lines. In addition, the authors investigated the methylation status of miR-137 in CRC tissues and its adjacent normal. They discovered that the methylation of miR-137 is tumor-specific, considering that higher methylation was significantly detected in CRCs compared with normal tissues. Interestingly, a similar methylation frequency of miR-137 was observed in CRCs and adenomas, indicating that the methylation of miR-137 may occur in the early event of colorectal carcinogenesis [35]. This finding is in agreement with Kashani et al. [36], in which methylation of miR-137 occurred in CRCs and no methylation was observed in normal tissues. In addition, this study revealed increased hypermethylation of miR-137 in patients with a family history of CRC or other gastrointestinal-related cancers. These encapsulate the crucial role of methylation in miR-137 as a diagnostic biomarker in CRC.

CRC arises from abnormal growth of colon epithelium and subsequently transforms to adenomatous polyps, which over time progress to cancer. A study by Huang et al. observed a gradual decrease in miR-137 expression during the process of colorectal carcinogenesis. Therefore, they postulated that DNA methylation subsequently downregulates miR-137 in polyps is an early event in the development of CRC [34]. As discussed earlier, methylation of miR-124 could be a valuable marker in identifying UC patients with high risk of developing CRC. In addition, the authors discovered the potential of methylation
in miR-137 as an independent risk factor in differentiating UC patients with high risk of developing CRC. Moreover, methylation of this microRNA showed a substantial AUC value in discriminating UC patients with high or low risk of developing cancer, further demonstrating its importance in CRC screening [29].

Dysregulation of miR-137 is associated with prognosis of CRC. The decline of miR-137 expression is able to predict recurrence and survival of stage II CRC patients [37]. Furthermore, altered miR-137 expression has been shown to be associated with the progression of CRC. Through an in vitro model, downregulation of this microRNA induces cell proliferation, migration, and invasion in CRC by hindering the expression of TCF4. However, miR-137 could also target other downstream genes in addition to TCF4 to promote tumor progression. A study by Sakaguchi et al. demonstrated the capability of ectopic expression of miR-137 to suppress the tumorigenicity of colon cancer stem cells without affecting normal cells. Furthermore, they discovered that the presence of miR-137 restrained the colon cancer metastasis through the downregulation of DCLK1 expression [38]. Interestingly, research by Chen et al. suggests that miR-137 expression in CRC is subject to epigenetic silencing mediated by MeCP2, a DNA methyl CpG binding protein. MeCP2 can directly bind to the promoter region of miR-137 and lead to a decrease in expression. Restoring the expression of miR-137 led to the inhibition of the colorectal tumor growth in a xenograft model, as well as in vivo hepatic metastasis [39].

2.3. MiRNA-34

MiR-34, a tumor suppressive microRNA family, has been observed to be directly regulated by the tumor suppressor p53 [40]. The miR-34 family consists of three members, including miR-34a, miR-34b, and miR-34c. Interestingly, three miR-34 family members are produced by two different transcriptional units [41]. Human miR-34a is located at chromosome 1p36.22, whereas miR-34b and miR-34c reside on chromosome 11q23.1 [41]. MiR-34 is frequently methylated in CRC tissues and to a lesser extent in adjacent normal tissues. Notably, Wu et al. [42] discovered that methylation of miR-34a was observed in 76.8% of CRCs and 5% of healthy volunteer stool samples. Intriguingly, miR-34b/c methylation was displayed in 93.6% of CRC stool samples and no methylation was observed in the healthy samples. This finding is consistent with those of Kalimutho et al., whereby they found that 75% of fecal CRC patients exhibited aberrant methylation of miR-34b/c [43]. High sensitivity detection of methylation miR-34b/c in stool samples may be an effective non-invasive screening method for the diagnosis of CRC.

MiR-34a expression is useful for CRC prognosis. Gao et al. evaluated the expression of miR-34a-5p in recurrence and non-recurrence groups of stage II and stage III CRC patients. Their results revealed that miR-34a-5p was downregulated in the recurrence group despite the TNM stage. In addition, the elevated expression of this microRNA was directly proportional to DFS. This suggests that miR-34a-5p is a potential prognostic marker to predict the aggressiveness of cancer in stage II and III CRCs. Moreover, the authors discovered that the inhibition of metastatic properties in CRCs is a p53-dependent manner [44]. The downregulation of miR-34a in CRC is presumably caused by the aberrant methylation at the promoter region. High methylation frequency of miR-34a has been observed in primary tumors that have developed liver and lymph node metastases. Furthermore, silencing of this microRNA was associated with an increased expression of c-Met and β-catenin, which exhibited pro-metastatic function. Therefore, the epigenetic silencing of miR-34a together with upregulation of c-Met and β-catenin in primary colon cancer may have a prognostic value to identify patients with a high risk of liver metastases [45].

However, two studies presented the opposite findings. Rapti et al. showed that miR-34a was overexpressed in poorly differentiated CRC, which is highest in grade III tumors as compared with the lower grades. Deregulation of this microRNA leads to worsened DFS and OS, independently of clinicopathological factors, such as tumor size, histological grade, tumor invasion, and nodal status apart from distant metastasis. Therefore, elevated miR-34a expression is a potential unfavorable prognosis marker in CRC [46]. Another
study by Hasakova et al. found that miR-34a-5p was upregulated in CRCs as compared with the adjacent tissues. Nevertheless, they found that the expression of miR-34a-5p varied in accordance with the sex, whereby downregulation of this microRNA was ascertained in male patients rather than females. In addition, a better survival rate was observed in male patients who exhibited high miR-34a-5p, and was unlikely associated with advanced stages [47]. A possible explanation of these contrasting results is the tumor microenvironment heterogeneity of CRCs.

2.4. Other microRNA Genes

MiR-133b is a tumor suppressor gene and is often silenced in CRC [48]. Silencing of this microRNA is correlated with CpG methylation in the promoter region. In addition, miR-133b was reported to be downregulated in the primary CRC and metastatic hepatic tissues. Remarkably, miR-133b negatively regulates the HOXA9/ZEB1 pathway, which then promotes tumor metastases and poor outcomes in CRCs [49]. DNA hypermethylation of miR-1 was first observed in hepatocellular carcinoma (HCC) primary tissues and cells [50]. Later, Chen et al. discovered the methylation of miR-1 in primary CRC tissues [51]. In addition, the DNA methylation-mediated downregulation of miR-1 was observed in 12 out of 14 colon cancer metastases. Interestingly, miR-1 was shown to interact with miR-133a in CRC and concurrent silencing of these microRNAs negatively regulate TAGLN2 expression. Therefore, miR-1-133a interaction with upregulation of TAGLN2 has a significant role in CRC metastasis.

The expression of miR-9 may be regulated by DNA methylation and histone modification in CRC. Methylation of this microRNA was detected in 56% of primary CRC. However, high methylation frequency was observed in advanced stages of CRC with regional nodal and vascular invasion aside from metastasis. The finding of this study showed that miR-9 silencing is crucially involved in CRC progression [52]. Moreover, deregulation of miR-9 has been reported to promote proliferation and tumor cell survival in CRC [53].

In addition to the microRNAs mentioned above, miR-345 and miR-342 are highly methylated, with low expression in CRCs in comparison with non-cancerous tissues [54,55]. Ectopic expression of these microRNAs is able to suppress colon cancer proliferation and invasiveness. Tang et al. discovered that miR-345 inhibits tumor growth by targeting BCL2-associated athanogene 3 (BAG3), a molecule that regulates the apoptosis process [54]. In contrast, restoration of miR-342 has been found to reduce the expression of DNMT1, which subsequently demethylates tumor suppressor genes, such as ADAM23, HINT1, RASSF1A, and RECK in CRC [55].

A non-exhaustive compiled summary of microRNA methylation implicated in CRC is presented in Table 1. Clearly, epigenome-wide profiling of microRNA methylation using high-throughput approaches, such as microarray or whole-genome bisulfide sequencing has not been performed, further highlighting the importance of our study. Finally, an illustration on the involvement of microRNA methylation in CRC progression is provided in Figure 2a,b.

| MicroRNA(s) and Reference | MicroRNA Methylation Detection Method | Types of Specimens | Key Findings |
|---------------------------|--------------------------------------|--------------------|--------------|
| miR-124a [17] Known targets: STAT3, IASPP, PRRX1, KITENIN, PRPS1, RPIA PTB1/PKM1/PKM2, DNMT3B, DNMT1, ROCK1, PRRX1, PLCB1 | Methylation-specific PCR (MSP) and bisulfite sequencing | Cell line model with disrupted DNA methyltransferase | Epigenetic silencing of miR-124a via CpG island hypermethylation leads to CDK6 oncoprotein activation and Rb phosphorylation |
### Table 1. Cont.

| MicroRNA(s) and Reference | MicroRNA Methylation Detection Method | Types of Specimens | Key Findings |
|--------------------------|--------------------------------------|--------------------|--------------|
| miR-34b/c [19] Known targets: SATB2 | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines | • miR-34b/c and NTG4 are novel tumor suppressors in CRC  
• miR-34b/c CpG island is a frequent target of epigenetic silencing in CRC |
| miR-133b [20] Known targets: CXCR4, HOXA9 | Methylation-specific PCR (MSP) and combined bisulfite restriction analysis (COBRA) | Screening using CRC cell lines and validation in the tissues (6 CRCs, 2 adjacent non-tumors, and 2 healthy colorectal tissues) | • miR-133b promoter hypermethylation is upregulated in CRC tissues  
The regulation of miR-133b methylation has potential therapeutic utility for CRC treatment |
| miR-324 [21] Known targets: ELAVL1 | Methylation-specific PCR (MSP) and bisulfite sequencing | 42 CRCs, 9 colorectal adenomas, and 16 normal mucosa in patients with and without CRC | • Methylation at the EVL/miR-324 locus was identified in 86% CRCs and in 67% adenomas, suggesting that it is an early event in CRC carcinogenesis |
| miR-137, miR-342 [36] Known targets: miR-137: TCF4, FNMI2, Aurora-A, miR-342: DNMT1, FOXM1, FOXQ1 | Methylation-specific PCR (MSP) | Fresh-frozen tissues (51 polyps, 8 tumors, and 14 normal mucosa) | • miR-137 hypermethylation is higher in male patients  
• miR-342 hypermethylation is associated with patients’ age |
| miR-9, miR-129, miR-137 [52] Known targets: miR-9: TM4SF1, FOXP2, ANO1, miR-129: MALAT1, miR-137: TCF4, FNMI2, Aurora-A | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and 50 primary CRCs with adjacent normal tissues | • miR-9-1, miR-129-2, and miR-137 methylation occurred commonly in CRC cell lines and primary CRC tumors, but not in normal colonic mucosa  
• miR-9-1 methylation was associated with lymph node metastasis |
| miR-345 [54] No known target | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and 31 CRC patients | • miR-345 hypermethylation was detected in tumor vs. normal tissues and is associated with its low expression, lymph node metastasis, and worse histological type |
| miR-129-2, miR-345, miR-132 [56] Known targets: miR-129: MALAT1, miR-345: No known target miR-132: ZEB2, ERK1 | Bisulfite sequencing and Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA) | CRC cell lines treated with 5-aza-2’ deoxycytidine followed by validation in 205 CRCs | • miR-345 and miR-132 hypermethylation is associated with a mismatch-repair deficiency in CRC  
• miR-132 hypermethylation distinguished sporadic MMR-deficient CRC from Lynch-CRC |
| miR-132 [57] Known targets: miR-132: ZEB2, ERK1 | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and 36 CRCs with adjacent normal tissues | • miR-132 is epigenetically silenced in CRC cell lines and implies a poor prognosis in CRC |
| MicroRNA(s) and Reference | MicroRNA Methylation Detection Method | Types of Specimens | Key Findings |
|--------------------------|--------------------------------------|-------------------|--------------|
| miR-1, miR-9, miR-124, miR-137 [29] | Quantitative bisulfite pyrosequencing | 387 colorectal epithelial specimens (362 non-neoplastic and 25 neoplastic tissues) | • Among patients with ulcerative colitis without neoplasia, the rectal tissues had significantly higher levels of microRNA methylation • Methylation level was associated with age and duration of ulcerative colitis |
| miR-125 [58] | Bisulfite sequencing PCR | CRC tissues and adjacent normal tissues from 68 CRC patients | Patients with hypermethylation of miR-125a and miR-125b had a shorter life expectancy than those with normal levels |
| miR-941 [59] | Bisulfite sequencing | CRC cell lines | • Hypermethylated in HCT116 cells • Suppresses cell growth and migration in CRC cells |
| miR-1237 [59] | Bisulfite sequencing | CRC cell lines | • Hypermethylated in HCT116 cells • Transcriptionally independent from the host gene |
| miR-1247 [60] | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and patients (hypermethylated and non-methylated CRCs) | • Downregulated in methylated CRC and hypermethylated cell lines (RKO, HCT116) • Novel tumor suppressor by targeting MYCBP2 in methylated CRC |
| miR-128 [61] | Bisulfite sequencing PCR | CRC cell lines and patients | miR-128 was epigenetically silenced by DNA methylation, implies a poor prognosis in CRC • Restoration of miR-128 could inhibit cell proliferation by inducing cell cycle arrest |
| miR-148a [62] | Bisulfite pyrosequencing | 273 CRC patients (76 stage II, 125 stage III, 72 stage IV) | • miR-148a was significantly downregulated in tumor stage III/IV and correlated with promoter hypermethylation • Low miR-148a expression leads to poor therapeutic response and patients’ overall survival |
| MicroRNA(s) and Reference | MicroRNA Methylation Detection Method | Types of Specimens | Key Findings |
|---------------------------|--------------------------------------|--------------------|--------------|
| miR-126 [63]              | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and patients | • Silencing of miR-126 in CRC tissue and cell lines was due to the promoter methylation.  
• Restoration of miR-126 inhibits VEGF expression, thus hindering tumor progression. |
| miR-27b [64]              | Methylation-specific PCR (MSP)        | CRC cell lines     | • DNA hypermethylation of miR-27b CpG island decreases miR-27b expression.  
• Targets VEGFC to inhibit tumor growth and angiogenesis in vivo. |
| miR-149 [65]              | Methylation-specific PCR (MSP)        | CRC cell lines     | • Treatment using polyphenol (BPIS) induces hypomethylation of miR-149 CpG island in HCT-8/Fu cells.  
• Upregulation of miR-149 improved chemosensitivity of CRC through miR-149/Akt-mediated cell cycle arrest. |
| miR-497/195 [66]          | Combined bisulfite restriction analysis (COBRA) and bisulfite genomic sequencing (BGS) | CRC cell lines and patients | • Both miRNAs were hypermethylated and under expressed in precancerous lesion.  
• Pri-miR-497/195 was monoallelic methylated at CpG island in normal colorectal and biallelic methylated in most colorectal adenomas. |
| miR-212 [67]              | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and tissues | • miR-212 was hypermethylated at upstream promoter region in CRC tissues and cell lines, but not in FHC cells.  
• Low miR-212 level associated with aggressive tumor phenotype and poor disease prognosis. |
| miR-200c/141 [68]         | Methylation-specific PCR (MSP)        | CRC tissues        | • miR-200c/141 cluster promoter region was significantly hypermethylated in colorectal tumors and adenomatous polyps, but not in hyperplastic polyp tissues. |
Table 1. Cont.

| MicroRNA(s) and Reference | MicroRNA Methylation Detection Method | Types of Specimens | Key Findings |
|--------------------------|--------------------------------------|--------------------|--------------|
| miR-373 [69]             | Methylation-specific PCR (MSP) and bisulfite sequencing | CRC cell lines and 40 CRC patients | • CpG island at promoter region of miR-373 was significantly hypermethylated in CRC tissues and cell lines  
• May inhibit cell viability in CRC cell lines by targeting oncogene RAB22A |

Known targets in CRC were identified using miRCancer database [70].

Figure 2. (a) Simplified illustration of microRNA and its potential involvement in CRC. DNA methylation is a key epigenetic mechanism for silencing RNA polymerase II-transcribed genes [71]. When the microRNA gene is methylated, no precursor microRNA will be transcribed, thus reducing its mature microRNA expression [72]. This in turn could lead to cancer formation, progression, and treatment resistance. (b) Simplified illustration of microRNA and its potential involvement and application in normal colon. The unmethylated microRNA gene will lead to transcription of microRNA precursor by RNA polymerase II, which will then be exported into the cytoplasm by Exportin 5, followed by processing with the RISC, which will result in target gene translation repression or mRNA degradation. As a result, oncogenic protein expression will be reduced.

As previously mentioned, the methylome profiles of microRNAs in CRC patients have not been extensively characterized. While there are several published findings from our research group on DNA methylation profiles in CRC [6,73], none have focused on microRNA methylome in detail. MicroRNAs are considered the master regulators that
control gene expression [74]. Therefore, research on the elements controlling microRNA is indispensable.

3. MicroRNA Methylation in CRC Chemoresistance

Emerging evidence has revealed that abnormal expression of miRNAs also plays a vital role in chemotherapeutic drug resistance. FOLFOX, which is a mixture of folic acid (FOL), 5-fluorouracil (F), and oxaliplatin (OX) [75], is one of the most extensively used chemotherapy regimens for the treatment of cancer, mainly CRC. While cancer treatment is progressing, the formation of chemoresistance clones have emerged as a significant obstacle in the clinic. Finding prospective biomarkers and therapeutic targets that could lead to an increase in the success rate of suggested therapies is critical to achieving a successful outcome. Since it has been established that microRNAs are significant participants in the biological system, researchers have become increasingly interested in understanding their functional activities. When it comes to overcoming chemoresistance to FOLFOX, microRNAs as post-transcriptional regulators have the potential to be extremely beneficial. A review on differentially expressed microRNAs involved in CRC chemoresistance was previously published by our group and should serve as complementary reading [76]. In this section, we will focus primarily on the methylated microRNAs and their roles in CRC chemoresistance.

MiR-26b expression was analyzed in 5-fluorouracil (5-FU) resistant CRC cell lines and parental cells. The results showed that miR-26b was significantly downregulated in the 5-FU resistant cell lines, and thus, it is probably involved in CRC chemoresistance. Importantly, the downregulation of miR-26b was associated with promoter methylation and treatment with a demethylating drug (5-aza-2'-deoxycytidine was able to restore the expression of miR-26b in resistant cell lines). Upregulation of miR-26b conferred 5-FU chemosensitivity by repressing PGP expression and further activating caspase-9 and caspase-3 [77].

Takahashi et al. have provided evidence that miR-148a is frequently downregulated through the promoter hypermethylation in the advanced CRC. Moreover, downregulation of miR-148a was significantly associated with a poor outcome in patients with stage III CRC treated with adjuvant 5-FU. In addition, low expression of this microRNA is associated with worse therapeutic response and survival rate in stage IV CRC patients treated with 5-FU and oxaliplatin chemotherapy [62].

Low expression of miR-181a, 135a, and 302c is mediated by DNA methylation in colon cancer. Shi et al. proved that dysregulation of these microRNAs promotes 5-FU resistance in microsatellite instable (MSI) CRC. Restoration of microRNAs expression attenuates PLAG1 expression and was shown to re-sensitize 5-FU resistant MSI CRC cell lines [78].

Another microRNA associated drug resistance is miR-149. A previous study showed that aberrant methylation is the main mechanism that is responsible for the silencing of miR-149 in CRC [79]. The expression of miR-149 is downregulated in 5-FU resistant cells as compared with their parental cells. Re-expression of this microRNA was able to enhance the 5-FU sensitivity of CRC cells by suppressing FOXM1 gene [80]. In addition, another recent study demonstrated that the upregulation of miR-149 expression together with the DNA de-methylation (5-aza-dc) therapy could positively elevate the chemosensitivity of CRC [65]. Similarly, the co-administration of dichloroacetate (DCA) and overexpression of miR-149 in CRC was shown to not only improve 5-Fu apoptosis, but also to help in minimizing glucose metabolism [81].

Other downregulated microRNAs, such as miR-200 [82], miR-17-5p [83], miR-124, miR-506 [84], miR-143 [85], and miR-340 [86] were associated with chemoresistance of multi-drugs in CRCs. The downregulation of these microRNAs was correlated with DNA methylation [87–90]. Considered together, these data suggest that epigenetic silencing of microRNAs has strong potential as a marker to predict chemotherapy response in CRC.
4. Conclusions

The methylation of a subset of microRNA genes could serve as a useful biomarker for the improvement of cancer detection and/or clinical outcome prediction. In addition, the restoration of epigenetically silenced tumor-suppressive microRNAs in cancer cells using the demethylating drugs could be a promising cancer treatment strategy. In the future, we envisage that further cancer epigenome and microRNA studies will lead to the discovery of a range of new biological markers and potential therapeutic targets.

Author Contributions: Conceptualization, N.S.A.M.; writing—original draft preparation, R.B. and N.Q.R.B.; writing—review and editing, N.S.A.M., I.I. and L.-H.L.; visualization, N.S.A.M.; supervision, N.S.A.M.; project administration, N.S.A.M.; funding acquisition, N.S.A.M. and L.-H.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Higher Education Malaysia, grant number FRGS/1/2020/SKK0/UKM/02/11. The APC was funded by Monash University Malaysia.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ezat, S.W.; Natrah, M.S.; Aljunid, S.; Rizal, M.A.; Saperi, S.; Ismail, S.; Fuad, I.; Azrif, M.A. Economic evaluation of monoclonal antibody in the management of colorectal cancer. J. Cancer Res. Ther. 2013, 1, 34–39.
2. Azzani, M.; Dahlui, M.; Ishak, W.Z.W.; Roslani, A.C.; Su, T.T. Provider costs of treating colorectal cancer in government hospital of Malaysia. Malays J. Med. Sci. 2019, 26, 73–86. [CrossRef] [PubMed]
3. Azizah, A.M.; Nor Saleha, I.T.; Noor Hashimah, A.; Asmah, Z.A.; Mastulu, W. Malaysian National Cancer Registry Report 2007–2011; National Cancer Institute: Putrajaya, Malaysia, 2016.
4. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [CrossRef]
5. Naumov, V.A.; Generozov, E.V.; Zaharjevskaya, N.B.; Matushkina, D.S.; Larin, A.K.; Chernyshov, S.V.; Alekseev, M.V.; Shelygin, Y.A.; Govorun, V.M. Genome-scale analysis of DNA methylation in colorectal cancer using infinium humanmethylation450 beadchips. Epigenetics 2013, 8, 921–934. [CrossRef] [PubMed]
6. Baharudin, R.; Ab Mutalib, N.-S.; Othman, S.N.; Sagap, I.; Rose, I.M.; Mohd Mokhtar, N.; Jamal, R. Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer. Front. Pharmacol. 2017, 8, 47. [CrossRef]
7. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
8. Zhang, Y.; Wang, J. MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol. Chem. 2017, 398, 929–938. [CrossRef]
9. Al-Akhrass, H.; Christou, N. The clinical assessment of microRNA diagnostic, prognostic, and theranostic value in colorectal cancer. Cancers 2021, 13, 2916. [CrossRef]
10. Imedio, L.; Cristóbal, I.; Rubio, J.; Santos, A.; Rojo, F.; García-Foncillas, J. MicroRNAs in rectal cancer: Functional significance and promising therapeutic value. Cancers 2020, 12, 2040. [CrossRef]
11. Pidíková, P.; Herichová, I. MiRNA clusters with up-regulated expression in colorectal cancer. Cancers 2021, 13, 2979. [CrossRef]
12. Svoronos, A.A.; Engelman, D.M.; Slack, F.J. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016, 76, 3666–3670. [CrossRef] [PubMed]
13. Kaur, S.; Lotsari-Salomaa, J.E.; Seppänen-Kajansinkko, R.; Peltomäki, P. MicroRNA methylation in colorectal cancer. In Non-Coding RNAs in Colorectal Cancer; Slaby, O., Calin, G.A., Eds.; Springer International Publishing: Cham, Switzerland, 2016; Volume 937, pp. 109–122. ISBN 978-3-319-42057-8.
14. Wang, S.; Wu, W.; Clare, F.X. Mutual regulation of micornas and DNA methylation in human cancers. Epigenetics 2017, 12, 187–197. [CrossRef] [PubMed]
15. Stark, V.A.; Facey, C.O.B.; Viswanathan, V.; Boman, B.M. The role of MiRNAs, MiRNA clusters, and isomirs in development of cancer stem cell populations in colorectal cancer. Int. J. Mol. Sci. 2021, 22, 1424. [CrossRef] [PubMed]
16. Lujambio, A.; Calin, G.A.; Villanueva, A.; Ropero, S.; Sanchez-Cespedes, M.; Blanco, D.; Montuenga, L.M.; Rossi, S.; Nicoloso, M.S.; Faller, W.J.; et al. A MicroRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105, 13556–13561. [CrossRef] [PubMed]
17. Lujambio, A.; Ropero, S.; Ballestar, E.; Fraga, M.F.; Cerrato, C.; Setién, F.; Casado, S.; Suárez-Gauthier, A.; Sanchez-Cespedes, M.; Git, A.; et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res.* 2007, 67, 1424–1429. [CrossRef] [PubMed]

18. Patil, N.; Abba, M.L.; Zhou, C.; Chang, S.; Gaiser, T.; Leupold, J.H.; Allgayer, H. Changes in methylation across structural and MicroRNA genes relevant for progression and metastasis in colorectal cancer. *Cancers* 2021, 13, 5951. [CrossRef]

19. Toyota, M.; Suzuki, H.; Sasaki, Y.; Maruyama, R.; Imai, K.; Shimomura, Y.; Tokino, T. Epigenetic silencing of MicroRNA-34b/c and B-cell translocation gene 4 is associated with cpg island methylation in colorectal cancer. *Cancer Res.* 2008, 68, 4123–4132. [CrossRef]

20. Lv, L.V.; Zhou, J.; Lin, C.; Hu, G.; Yi, L.U.; Du, J.; Gao, K.; Li, X. DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells. *Oncol. Lett.* 2015, 10, 907–912. [CrossRef]

21. Grady, W.M.; Parkin, R.K.; Mitchell, P.S.; Lee, J.H.; Kim, Y.-H.; Tsuchiya, K.D.; Washington, M.K.; Parasekova, C.; Willson, J.K.V.; Kaz, A.M.; et al. Epigenetic silencing of the intronic MicroRNA Hsa-MiR-342 and Its host gene EVL in colorectal cancer. *Oncogene* 2008, 27, 3880–3888. [CrossRef]

22. Oltira, S.S.; Peña-Chilet, M.; Vidal-Tomas, M.; Flower, K.; Martinez, M.T.; Alonso, E.; Burgues, O.; Lluch, A.; Flanagan, J.M.; Ribas, G. Methylation deregulation of miRNA promoters identifies MiR124-2 as a survival biomarker in breast cancer in very young women. *Sci. Rep.* 2018, 8, 1–12. [CrossRef]

23. Zhang, J.; Shi, K.; Huang, W.; Weng, W.; Zhang, Z.; Guo, Y.; Deng, T.; Xiang, Y.; Ni, X.; Chen, B.; et al. The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma. *Cancer Cell Int.* 2019, 19, 107. [CrossRef] [PubMed]

24. Roy, R.; Chatterjee, A.; Das, D.; Ray, A.; Singh, R.; Chattopadhyay, E.; Sarkar, N.D.; Eccles, M.; Pal, M.; Maitra, A.; et al. Genome-wide MiRNA methylation analysis in oral cancer: Possible biomarkers associated with patient survival. *Epigenomics* 2019, 11, 473–487. [CrossRef] [PubMed]

25. Lujambio, A.; Esteller, M. CpG island hypermethylation of tumor suppressor MicroRNAs in human cancer. *Cell Cycle* 2007, 6, 1455–1459. [CrossRef]

26. Hibner, G.; Kimsa-Furdzik, M.; Francuz, T. Relevance of MicroRNAs as potential diagnostic and prognostic markers in colorectal cancer. *Int. J. Mol. Sci.* 2018, 19, 2944. [CrossRef] [PubMed]

27. Harada, T.; Yamamoto, E.; Yamano, H.; Nojima, M.; Maruyama, R.; Kumegawa, K.; Ashida, M.; Yoshikawa, K.; Kimura, T.; Harada, E.; et al. Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. *Cancer Prev. Res.* 2014, 7, 1002–1010. [CrossRef]

28. Ueda, Y.; Ando, T.; Nanjo, S.; Ushijima, T.; Sugiyama, T. DNA methylation of MicroRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. *Dig. Dis. Sci.* 2014, 59, 2444–2451. [CrossRef]

29. Toiyama, Y.; Okugawa, Y.; Tanaka, K.; Araki, T.; Uchida, K.; Hishida, A.; Uchino, M.; Ikeuchi, H.; Hirota, S.; Kusunoki, M.; et al. A panel of methylated MicroRNA biomarkers for identifying high-risk patients with ulcerative colitis-associated colorectal cancer. *Gastroenterology* 2017, 153, 1634.e8–1646.e8. [CrossRef]

30. Wang, M.-J.; Li, Y.; Wang, R.; Wang, C.; Yu, Y.-Y.; Yang, L. Downregulation of MicroRNA-124 is an independent prognostic factor in patients with colorectal cancer. *Int. J. Colorectal Dis.* 2013, 28, 183–189. [CrossRef]

31. Jinushi, T.; Shibayama, Y.; Kinoshita, I.; Ozumi, S.; Jinushi, M.; Aota, T.; Takahashi, T.; Horita, S.; Dosaka-Akita, H.; Iseki, K. Low expression levels of MicroRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. *Cancer Med.* 2014, 3, 1544–1552. [CrossRef]

32. Zhou, L.; Xu, Z.; Ren, X.; Chen, K.; Xin, S. MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating rho-associated protein kinase 1 (ROCK1). *CPB* 2016, 38, 1785–1795. [CrossRef]

33. Mahmoudi, E.; Cairns, M.J. MiR-137: An important player in neural development and neoplastic transformation. *Cell Cycle* 2017, 22, 44–55. [CrossRef] [PubMed]

34. Huang, Y.-C.; Lee, C.-T.; Lee, J.-C.; Liu, Y.-W.; Chen, Y.-J.; Tseng, J.T.; Kang, J.-W.; Sheu, B.-S.; Lin, B.-W.; Hung, L.-Y. Epigenetic silencing of MiR-137 contributes to early colorectal carcinogenesis by impaired aurora—A inhibition. *Oncotarget* 2016, 7, 76852–76866. [CrossRef] [PubMed]

35. Balagué, F.; Link, A.; Lozano, J.J.; Cuatrecasas, M.; Nagasaka, T.; Boland, C.R.; Goel, A. Epigenetic silencing of MiR-137 is an early event in colorectal carcinogenesis. *Cancer Res.* 2010, 70, 6609–6618. [CrossRef] [PubMed]

36. Kashani, E.; Hadizadeh, M.; Chaloshi, V.; Mirfakhraie, R.; Young, C.; Savabkar, S. The differential DNA hypermethylation patterns of MicroRNA-137 and MicroRNA-342 locus in early colorectal lesions and tumours. *Biomolecules* 2019, 9, 519. [CrossRef]

37. Bahnassy, A.A.; El-Sayed, M.; Ali, N.M.; Khorshid, O.; Hussein, M.M.; Youssef, H.F.; Mohamed, M.A.; Zekri, A.-R.N.; Salem, S.E. Aberrant expression of miRNAs predicts recurrence and survival in stage-II colorectal cancer patients from Egypt. *Appl. Cancer Res.* 2021, 39, 7281–7288. [CrossRef]

38. Sakaguchi, M.; Hisamori, S.; Oshima, N.; Sato, F.; Shimonoy, Y.; Sakai, Y. MiR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1. *Mol. Cancer Res.* 2016, 14, 354–362. [CrossRef]

39. Chen, T.; Cai, S.-L.; Li, J.; Qi, Z.-P.; Li, X.-Q.; Ye, L.-C.; Xie, X.-F.; Hou, Y.-Y.; Yao, L.-Q.; Xu, M.-D.; et al. Mecp2-Mediated epigenetic silencing of MiR-137 contributes to colorectal adenoma-carcinoma sequence and tumor progression via relieving the suppression of c-met. *Sci. Rep.* 2017, 7, 44543. [CrossRef]
40. Navarro, F.; Lieberman, J. MiR-34 and P53: New insights into a complex functional relationship. PLoS ONE 2015, 10, e0132767. [CrossRef]

41. Zhang, L.; Liao, Y.; Tang, L. MicroRNA-34 family: A potential tumor suppressor and therapeutic candidate in cancer. J. Exp. Clin. Cancer Res. 2019, 38, 53. [CrossRef]

42. Wu, X.; Song, Y.-C.; Cao, P.-L.; Zhang, H.; Guo, Q.; Yan, R.; Diao, D.-M.; Cheng, Y.; Dang, C.-X. Detection of MiR-34a and MiR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. Med. Oncol. 2014, 31, 894. [CrossRef]

43. Kalimutho, M.; Di Cecilia, S.; Del Vecchio Blanco, G.; Roviello, F.; Sileri, P.; Cretella, M.; Formosa, A.; Corso, G.; Marrelli, D.; Pallone, F.; et al. Epigenetically silenced MiR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer 2011, 104, 1770–1778. [PubMed]

44. Gao, J.; Li, N.; Dong, Y.; Li, S.; Xu, L.; Li, X.; Li, Y.; Li, Z.; Ng, S.S.; Sung, J.J.; et al. MiR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene 2015, 34, 4142–4152. [CrossRef] [PubMed]

45. Siemens, H.; Neumann, J.; Jackstadt, R.; Mansmann, U.; Horst, D.; Kirchner, T.; Hermeking, H. Detection of MiR-34a promoter methylation in combination with elevated expression of c-met and β-catenin predicts distant metastasis of colon cancer. Clin. Cancer Res. 2013, 19, 710–720. [CrossRef] [PubMed]

46. Rapti, S.-M.; Kontos, C.K.; Christodoulou, S.; Papadopoulos, I.N.; Scorilas, A. MiR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. Clin. Biochem. 2017, 50, 918–924. [CrossRef]

47. Hasakova, K.; Reis, R.; Vician, M.; Zeman, M.; Herichova, I. Expression of MiR-34a-5p is up-regulated in human colorectal cancer and correlates with survival and clock gene PER2 expression. PLoS ONE 2019, 14, e0224396. [CrossRef]

48. Li, D.; Xia, L.; Chen, M.; Lin, C.; Wu, H.; Zhang, Y.; Pan, S.; Li, X. MiR-133b, a particular member of myomirs, coming into playing its unique pathological role in human cancer. Oncotarget 2017, 8, 50193–50208. [CrossRef]

49. Wang, X.; Bu, J.; Liu, X.; Wang, W.; Mai, W.; Lv, B.; Zou, J.; Mo, X.; Li, X.; Wang, J.; et al. MiR-133b suppresses metastasis by targeting HOXA9 in human colorectal cancer. Oncotarget 2017, 8, 63935–63948. [CrossRef]

50. Datta, J.; Kutay, H.; Nasser, M.W.; Nuovo, G.; Wang, B.; Majumder, S.; Liu, C.-G.; Volinia, S.; Croce, C.M.; Schmittgen, T.D.; et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68, 5049–5058. [CrossRef]

51. Chen, W.-S.; Leung, C.-M.; Pan, H.-W.; Hu, L.-Y.; Li, S.-C.; Ho, M.-R.; Tsai, K.-W. Silencing of MiR-1-1 and MiR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol. Rep. 2012, 28, 1069–1076. [CrossRef]

52. Bandres, E.; Agirre, X.; Bitarte, N.; Ramirez, N.; Zarate, R.; Roman-Gomez, J. Epigenetic regulation of MicroRNA expression in colorectal cancer. Int. J. Cancer 2009, 125, 2737–2743. [CrossRef]

53. Cekaite, L.; Rantala, J.K.; Bruun, J.; Guriby, M.; Ágesen, T.H.; Danielsen, S.A.; Lind, G.E.; Nesbakken, A.; Kallioniemi, O.; Lothe, R.A.; et al. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012, 14, 868–881. [CrossRef] [PubMed]

54. Tang, J.-T.; Wang, J.-L.; Du, W.; Hong, J.; Zhao, S.-L.; Wang, Y.-C.; Xiong, H.; Chen, H.-M.; Fang, J.-Y. MicroRNA 345, a methylation-sensitive MicroRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011, 32, 1207–1215. [CrossRef] [PubMed]

55. Wang, H.; Wu, J.; Meng, X.; Ying, X.; Zuo, Y.; Liu, R.; Pan, Z.; Kang, T.; Huang, W. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011, 32, 1033–1042. [CrossRef] [PubMed]

56. Kaur, S.; Lotsari, J.E.; Al-Soihail, S.; Warusavitarne, J.; Kohonen-Corish, M.R.; Peltomäki, P. Identification of subgroup-specific MiRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. Clin. Epigenetics 2015, 7, 20. [CrossRef]

57. Wang, Z.; Qin, J.; Ke, J.; Wang, F.; Zhou, Y.; Jiang, Y.; Xu, J. Downregulation of MicroRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer. OncoTargets Ther. 2015, 8, 3639. [CrossRef]

58. Chen, H.; Xu, Z. Hypermethylation-associated silencing of MiR-125a and MiR-125b: A potential marker in colorectal cancer. Dis. Markers 2015, 2015, 345080. [CrossRef]

59. Yan, H.; Choi, A.; Lee, B.H.; Ting, A.H. Identification and functional analysis of epigenetically silenced microRNAs in colorectal cancer cells. PLoS ONE 2011, 6, e20628. [CrossRef]

60. Liang, J.; Zhou, W.; Sakre, N.; DeVecchio, J.; Ferrandon, S.; Ting, A.H.; Bao, S.; Bissett, I.; Church, J.; Kalady, M.F. Epigenetically regulated MiR-1247 functions as a novel tumour suppressor via MYCBP2 in methylator colon cancers. Br. J. Cancer 2018, 119, 1267–1277. [CrossRef]

61. Takahashi, Y.; Iwaya, T.; Sawada, G.; Kurashige, J.; Matsumura, T.; Uchi, R.; Ueo, H.; Takano, Y.; Eguchi, H.; Sudo, T.; et al. Up-regulation of NEK2 by MicroRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann. Surg. Oncol. 2014, 21, 205–212. [CrossRef] [PubMed]
63. Zhang, Y.; Wang, X.; Xu, B.; Wang, B.; Wang, Z.; Liang, Y.; Zhou, J.; Hu, J.; Jiang, B. Epigenetic silencing of MiR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep. 2013, 30, 1976–1984. [CrossRef] [PubMed]

64. Ye, J.; Wu, X.; Wu, D.; Pu, P.; Ni, C.; Zhang, Z.; Chen, Z.; Qiu, F.; Xu, J.; Huang, J. MiRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS ONE 2013, 8, e66087. [CrossRef] [PubMed]

65. Shan, S.; Lu, Y.; Zhang, X.; Shi, J.; Li, H.; Li, Z. Inhibitory effect of bound polyphenol from foxtail millet bran on MiR-149 methylation increases the chemosensitivity of human colorectal cancer HCT-8/Fu cells. Mol. Cell Biochem. 2021, 476, 513–523. [CrossRef] [PubMed]

66. Menigatti, M.; Staiano, T.; Manser, C.; Bauerfeind, P.; Komiljenovic, A.; Robinson, M.; Jiricny, J.; Buffoli, F.; Marra, G. Epigenetic silencing of monoallelically methylated MiRNA loci in precancerous colorectal lesions. Oncogenesis 2013, 2, e56. [CrossRef]

67. Meng, X.; Wu, J.; Pan, C.; Wang, H.; Ying, X.; Zhou, Y.; Hu, Y.; Zuo, Y.; Pan, Z.; Liu, R.-Y.; et al. Genetic and epigenetic down-regulation of MicroRNA-212 promotes colorectal tumor metastasis via dysregulation of MsnSOD. Gastroenterology 2013, 145, 426.e1–436.e1–6. [CrossRef]

68. Taheri, Z.; Asadazadeh Aghdaei, H.; Irani, S.; Modarressi, M.H.; Noormohammadi, Z. Clinical correlation of MiR-200c/141 cluster DNA methylation and MiR-141 expression with the clinicopathological features of colorectal primary lesions/tumors. Rep. Biochem. Mol. Biol. 2019, 8, 208–215.

69. Tanaka, T.; Arai, M.; Wu, S.; Kanda, T.; Miyaucha, H.; Imazeki, F.; Matsubara, H.; Yokosuka, O. Epigenetic silencing of MicroRNA-373 plays an important role in regulating cell proliferation in colon cancer. Oncol. Rep. 2011, 26, 1329–1335. [CrossRef]

70. Xie, B.; Ding, Q.; Han, H.; Wu, D. MiRCancer: A microRNA–Cancer association database constructed by text mining on literature. Bioinformatics 2009, 25, 638–644. [CrossRef]

71. Glaic, O.; Parikh, S.; Bell, R.E.; Mekahel, K.; Donyo, M.; Leader, Y.; Shayevitch, R.; Sheinboim, D.; Yannai, S.; Hollander, D.; et al. DNA methylation directs MicroRNA biogenesis in mammalian cells. Nat. Commun. 2019, 10, 5657. [CrossRef]

72. Suzuki, H.; Maruyama, R.; Yamamoto, E.; Kai, M. DNA methylation and microRNA dysregulation in cancer. Mol. Oncol. 2012, 6, 567–578. [CrossRef]

73. Kok-Sin, T.; Mohktar, N.M.; Hassan, N.Z.A.; Sagap, I.; Rose, I.M.; Harun, R.; Jamal, R. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol. Rep. 2015, 34, 22–32. [CrossRef] [PubMed]

74. Garofalo, M.; Croce, C.M. MicroRNAs: Master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 25–43. [CrossRef] [PubMed]

75. André, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; et al. Oxaliplatin, leucovorin, and 5-fluorouracil as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004, 350, 2343–2351. [CrossRef]

76. Hon, K.W.; Abu, N.; Ab Mutalib, N.-S.; Jamal, R. MiRNAs and LncRNAs as predictive biomarkers of response to FOLFOX therapy in colorectal cancer. Front. Pharmacol. 2018, 9, 846. [CrossRef] [PubMed]

77. Wang, B.; Lu, F.-Y.; Shi, R.-H.; Feng, Y.-D.; Zhao, X.-D.; Lu, Z.-P.; Xiao, L.; Zhou, G.-Q.; Qiu, J.-M.; Cheng, C.-E. MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of pgp. Am. J. Cancer Res. 2018, 8, 2518–2527.

78. Shi, L.; Li, X.; Wu, Z.; Li, X.; Nie, J.; Guo, M.; Mei, Q.; Han, W. DNA methylation-mediated repression of MiR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. J. Genet. Genom. 2018, 45, 205–214. [CrossRef]

79. Wang, F.; Ma, Y.-L.; Zhang, P.; Shen, T.-Y.; Shi, C.-Z.; Yang, Y.-Z.; Moyer, M.-P.; Zhang, H.-Z.; Chen, H.-Q.; Liang, Y.; et al. SP1 mediates the link between the tumor suppressor MiR-149 and outcome in colorectal cancer. J. Pathol. 2013, 229, 12–24. [CrossRef]

80. Liu, X.; Xie, T.; Mao, X.; Xue, L.; Chu, X.; Chen, L. MicroRNA-149 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by targeting forkhead box transcription factor FOXM1. CPB 2016, 39, 617–629. [CrossRef] [PubMed]

81. Liang, Y.; Hou, L.; Li, L.; Li, L.; Zou, L.; Wang, Y.; Huang, X.; Hou, Y.; Zhu, D.; Zou, H.; et al. Dichloroacetate restores colorectal cancer chemosensitivity through the P53/MiR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene 2020, 39, 469–485. [CrossRef]

82. Senfter, D.; Holzner, S.; Kalipciyan, M.; Staribacher, A.; Walzl, A.; Huttary, N.; Krieger, S.; Brenner, S.; Jäger, W.; Krupitza, G.; et al. Loss of MiR-200 family in 5-fluorouracil resistant colon cancer drives lymphphendothelial invasiveness in vitro. Hum. Mol. Genet. 2015, 24, 3689–3698. [CrossRef]

83. Fang, L.; Li, H.; Wang, L.; Hu, J.; Jin, T.; Wang, J.; Yang, B.B. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumor metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014, 5, 2974–2987. [CrossRef] [PubMed]

84. Chen, Z.; Liu, S.; Tian, L.; Wu, M.; Ai, F.; Tang, W.; Zhao, L.; Ding, J.; Zhang, L.; Tang, A. MiR-124 and MiR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget 2015, 6, 38139–38150. [CrossRef] [PubMed]

85. Qian, X.; Yu, J.; Yin, Y.; He, J.; Wang, L.; Li, Q.; Zhang, L.-Q.; Li, C.-Y.; Shi, Z.-M.; Xu, Q.; et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013, 12, 1385–1394. [CrossRef] [PubMed]

86. Zhang, L.-L.; Xie, F.-J.; Tang, C.-H.; Xu, W.-R.; Ding, X.-S.; Liang, J. MiR-340 suppresses tumor growth and enhances chemosensitivity of colorectal cancer by targeting RLIP76. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 2875–2886.
87. O’Brien, S.J.; Carter, J.V.; Burton, J.F.; Oxford, B.G.; Schmidt, M.N.; Hallion, J.C.; Galandiuk, S. The role of the MiR-200 family in epithelial–mesenchymal transition in colorectal cancer: A systematic review. *Int. J. Cancer* 2018, 142, 2501–2511. [CrossRef] [PubMed]

88. Konno, M.; Koseki, J.; Asai, A.; Yamagata, A.; Shimamura, T.; Motooka, D.; Okuzaki, D.; Kawamoto, K.; Mizushima, T.; Eguchi, H.; et al. Distinct methylation levels of mature microRNAs in gastrointestinal cancers. *Nat. Commun.* 2019, 10, 1–7. [CrossRef]

89. Ng, E.K.O.; Tsang, W.P.; Ng, S.S.M.; Jin, H.C.; Yu, J.; Li, J.J.; Röcken, C.; Ebert, M.P.A.; Kwok, T.T.; Sung, J.J.Y. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. *Br. J. Cancer* 2009, 101, 699–706. [CrossRef]

90. Huang, Z.; Li, Q.; Luo, K.; Zhang, Q.; Geng, J.; Zhou, X.; Xu, Y.; Qian, M.; Zhang, J.; Ji, L.; et al. MiR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. *Cell Death Dis.* 2019, 10, 372. [CrossRef]